<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00061867</url>
  </required_header>
  <id_info>
    <org_study_id>CELSION-10302101</org_study_id>
    <secondary_id>CDR0000301761</secondary_id>
    <secondary_id>RPCI-DS-0228</secondary_id>
    <nct_id>NCT00061867</nct_id>
  </id_info>
  <brief_title>Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer</brief_title>
  <official_title>A Dose Escalation, Pharmacokinetics, and Safety Study of Doxorubicin Encapsulated in Temperature Sensitive Liposomes Released Through Microwave Therapy in the Treatment of Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celsion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, use different ways to&#xD;
      stop tumor cells from dividing so they stop growing or die. Microwave thermotherapy kills&#xD;
      tumor cells by heating them to several degrees above body temperature. Combining liposomal&#xD;
      doxorubicin with microwave thermotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of liposomal&#xD;
      doxorubicin when given together with microwave thermotherapy in treating patients with&#xD;
      prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of doxorubicin HCl liposome released through&#xD;
           thermal microwave therapy in patients with adenocarcinoma of the prostate.&#xD;
&#xD;
        -  Determine the pharmacokinetics and biodistribution profile of this drug in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the safety profile and dose-limiting toxicity of this drug in these patients.&#xD;
&#xD;
        -  Determine the clinical response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive doxorubicin HCl liposome IV over 30 minutes. Patients then undergo a&#xD;
      60-minute course of prostate thermotherapy. Treatment may repeat every 28-42 days for up to 6&#xD;
      courses, at the discretion of the physician.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at 8, 15, 30, and 90 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hyperthermia treatment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Rising prostate-specific antigen AND radiographic evidence of extraprostatic prostate&#xD;
             cancer by bone scan, CT scan, prostascint scan, or MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  40 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC greater than 4,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 10.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST normal&#xD;
&#xD;
          -  Alkaline phosphatase normal&#xD;
&#xD;
          -  No acute or chronic liver disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 1.5 times upper limit of normal&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction at least 50% by MUGA&#xD;
&#xD;
          -  EKG normal&#xD;
&#xD;
          -  No myocardial infarction or cerebral vascular accident within the past 6 months&#xD;
&#xD;
          -  No life threatening cardiac arrhythmias&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No cardiac pacemaker&#xD;
&#xD;
          -  No peripheral arterial disease with intermittent claudication or Leriches syndrome&#xD;
             (i.e., claudication of the buttocks or perineum)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for 3 months&#xD;
             after study participation&#xD;
&#xD;
          -  No sperm donation during and for 3 months after study participation&#xD;
&#xD;
          -  Not febrile&#xD;
&#xD;
          -  No interest in future fertility or fathering children&#xD;
&#xD;
          -  No significantly decreased pain response&#xD;
&#xD;
          -  No severe urethral stricture&#xD;
&#xD;
          -  No protruding median lobe resulting in a &quot;ball-valve&quot; type of obstruction at the&#xD;
             bladder neck&#xD;
&#xD;
          -  No major psychiatric illness that would prevent informed consent&#xD;
&#xD;
          -  No major psychiatric illness that required inpatient treatment within the past 3&#xD;
             months&#xD;
&#xD;
          -  No psychological, family, sociological, or geographic condition that would preclude&#xD;
             study compliance&#xD;
&#xD;
          -  No allergy to eggs or egg products&#xD;
&#xD;
          -  No urinary or prostatic infection&#xD;
&#xD;
          -  No full urinary retention&#xD;
&#xD;
          -  No penile or urinary sphincter implant&#xD;
&#xD;
          -  No metallic implants in the pelvic or femoral area&#xD;
&#xD;
          -  No other serious medical illness that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent live vaccines&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior anthracycline&#xD;
&#xD;
          -  No concurrent streptozocin&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent hormonal therapy (except luteinizing hormone-releasing hormone analog)&#xD;
&#xD;
          -  No concurrent glucocorticoids administered at more than physiologic replacement doses&#xD;
             (other than as an antiemetic)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 3 months since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior therapy that resulted in permanent reduction of pain response (e.g., prior&#xD;
             surgery, regional or local anesthetic)&#xD;
&#xD;
          -  No concurrent PC-SPES&#xD;
&#xD;
          -  No concurrent cyclosporine, phenobarbital, or phenytoin&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Van Doren, RN</last_name>
    <role>Study Chair</role>
    <affiliation>Celsion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regional Urology, L.L.C.</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Strand Urology LLP</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2005</verification_date>
  <study_first_submitted>June 5, 2003</study_first_submitted>
  <study_first_submitted_qc>June 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2003</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

